RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is set to release its financial outcomes for the first quarter ended March 31, 2024, showcasing its latest performance metrics before the stock market opens on Thursday, May 9, 2024. The biopharmaceutical company, known for its focus on cardiovascular diseases, invites interested parties to join a conference call and webcast discussing these results in detail.
Scheduled for 8:30 a.m. ET on the same day, the call will accommodate participants from both domestic and international locations, with dial-in numbers 1-888-886-7786 or 1-416-764-8658. The conference ID for this critical financial briefing is 93715931. Additionally, a live webcast will be accessible, offering an alternative platform for stakeholders to engage directly with the company’s leadership about its Q1 achievements and future prospects.
This financial disclosure event is expected to offer insights into Mineralys Therapeutics’ progress and strategic direction, coming off a pivotal period of research and development activities. With a view towards enhancing shareholder value and advancing its pipeline, the company aims to address key questions and outline its vision moving forward.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.